NASDAQ$NDSN
Nordson Corporation · Q4 2023 earnings
Q4 2023 earnings · · Investor relations
Briefing
Reported a 5% increase in sales and record EBITDA for the quarter, driven by medical interventional solutions and industrial precision product lines.
Nordson Corporation reported a 5% increase in sales to $719 million and a record EBITDA of $227 million for the fourth quarter of fiscal year 2023. The company's performance was driven by strong growth in medical interventional solutions, industrial coatings, and polymer processing product lines, which offset weakness in electronics dispense and biopharma product lines. Adjusted earnings per diluted share were $2.46, compared to $2.44 in the prior year.
- Sales increased by 5% to $719 million compared to the prior year.
- EBITDA reached a quarterly record of $227 million, representing 32% of sales.
- Earnings per diluted share were $2.22.
- Adjusted earnings per diluted share were $2.46.
Headline financials
Revenue & EPS history
Nordson · Revenue · Quarterly
$719M
Revenue by segment
Nordson · $719M total across 3 segments · Q4 2023
- Industrial Precision Solutions$405M+13.8%56.3%
- Medical and Fluid Solutions$169M-6.6%23.5%
- Advanced Technology Solutions$145M-1.4%20.2%
Forward guidance
The company anticipates delivering sales growth in the range of 4% to 9% in fiscal 2024 when compared to fiscal 2023. Full year fiscal 2024 adjusted earnings are forecasted in the range of 1% to 8% growth per diluted share. First quarter fiscal 2024 sales are forecasted in the range of $615 to $640 million with adjusted earnings in the range of $2.00 to $2.10 per diluted share.
Tailwinds
- Sales growth in the range of 4% to 9% in fiscal 2024
- Adjusted earnings forecasted in the range of 1% to 8% growth per diluted share in fiscal 2024
- First quarter fiscal 2024 sales are forecasted in the range of $615 to $640 million
- Adjusted earnings in the range of $2.00 to $2.10 per diluted share for the first quarter of fiscal 2024
- Approximately $800 million in backlog
Headwinds
- Unfavorable book-to-bill in the fourth quarter and the majority of 2023
- Over $200 million in backlog was consumed
- Electronics dispense product lines softness
- Biopharma end markets demand weakness persisted
- Higher interest expense
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2023
+0.3%
Avg return
Earnings day
+0.2%
Avg return
5 days after
-0.5%
Avg return
30 days after
54%
37 / 69 earnings
Positive
+15.8%
Q4 2017
Best reaction
-14.8%
Q3 2015
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2026 | +1.8% | — | — | |
| Q1 2026 | -1.7% | -1.5% | -12.2% | |
| Q4 2025 | -0.3% | +0.0% | +10.5% | |
| Q3 2025 | +2.9% | +6.0% | +5.4% | |
| Q2 2025 | +6.8% | +8.5% | +9.9% | |
| Q1 2025 | +0.3% | -1.3% | -6.4% | |
| Q4 2024 | -9.4% | -11.4% | -20.9% | |
| Q3 2024 | +6.9% | +7.4% | +6.7% | |
| Q2 2024 | -10.5% | -12.4% | -14.5% | |
| Q1 2024 | +3.5% | +2.6% | +1.7% | |
| Q4 2023 | +5.1% | +7.1% | +5.8% | |
| Q3 2023 | +1.5% | +2.7% | -2.0% | |
| Q2 2023 | +1.1% | +1.7% | +8.8% | |
| Q1 2023 | -13.9% | -10.5% | -15.6% | |
| Q4 2022 | +1.5% | -2.1% | +2.3% | |
| Q3 2022 | -2.1% | -4.7% | -10.4% | |
| Q2 2022 | +2.7% | +7.1% | -3.8% | |
| Q1 2022 | -3.5% | -0.9% | -1.1% | |
| Q4 2021 | -5.9% | -7.2% | -9.9% | |
| Q3 2021 | +2.2% | +3.4% | +4.0% | |
| Q2 2021 | +7.4% | +9.8% | +8.0% | |
| Q1 2021 | -0.0% | +2.4% | +6.3% | |
| Q4 2020 | -2.9% | -0.5% | +1.2% | |
| Q3 2020 | -7.1% | -8.5% | -6.6% | |
| Q2 2020 | +1.7% | +1.0% | +12.4% | |
| Q1 2020 | -0.3% | -4.6% | -37.9% | |
| Q4 2019 | -1.6% | -0.5% | -1.2% | |
| Q3 2019 | -3.0% | -4.6% | +5.9% | |
| Q2 2019 | -1.0% | -5.4% | -1.6% | |
| Q1 2019 | -3.0% | -0.5% | -8.1% | |
| Q4 2018 | +7.7% | +3.7% | +10.9% | |
| Q3 2018 | -0.9% | +0.7% | +7.1% | |
| Q2 2018 | -4.2% | -5.5% | -3.3% | |
| Q1 2018 | -2.0% | -1.3% | -3.9% | |
| Q4 2017 | +15.8% | +14.5% | +19.5% | |
| Q3 2017 | -10.2% | -12.3% | -5.3% | |
| Q2 2017 | -5.9% | -7.6% | -8.2% | |
| Q1 2017 | +0.1% | +0.5% | +2.0% | |
| Q4 2016 | +5.2% | +7.2% | +7.0% | |
| Q3 2016 | +10.6% | +8.0% | +7.1% | |
| Q2 2016 | +15.7% | +16.8% | +12.2% | |
| Q1 2016 | +9.1% | — | — | |
| Q4 2015 | -8.1% | — | — | |
| Q3 2015 | -14.8% | — | — | |
| Q2 2015 | -1.4% | — | — | |
| Q1 2015 | +0.0% | — | — | |
| Q4 2014 | +2.3% | — | — | |
| Q3 2014 | +0.8% | — | — | |
| Q2 2014 | +9.2% | — | — | |
| Q1 2014 | +2.0% | — | — | |
| Q4 2013 | -2.3% | — | — | |
| Q3 2013 | +0.1% | — | — | |
| Q2 2013 | -7.4% | — | — | |
| Q1 2013 | -9.8% | — | — | |
| Q4 2012 | -1.4% | — | — | |
| Q3 2012 | +10.6% | — | — | |
| Q2 2012 | +10.5% | — | — | |
| Q1 2012 | +5.0% | — | — | |
| Q4 2011 | -1.9% | — | — | |
| Q3 2011 | -3.0% | — | — | |
| Q2 2011 | -1.1% | — | — | |
| Q1 2010 | +1.5% | — | — | |
| Q1 2011 | +3.3% | — | — | |
| Q2 2010 | +2.1% | — | — | |
| Q4 2010 | +2.1% | — | — | |
| Q4 2008 | +2.1% | — | — | |
| Q4 2009 | +0.2% | — | — | |
| Q3 2009 | +0.2% | — | — | |
| Q3 2010 | +0.2% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro